KRAS and familial pancreatic carcinoma: showed that Cas13 effectors can also be considered for therapeutic knockdown of oncogenes for which the use of small molecule inhibitors has thus far proven unsuccessful.[45] Programmed by crRNA to specifically target oncogenic kirsten rat sarcoma virus (KRAS) mutant and not wild‐type KRAS mRNA transcripts, LwaCas13a efficiently decreased levels of mutant KRAS mRNA, inducing cell apoptosis in pancreatic cancer cells and tumor shrinkage in mice with pancreatic cell xenografts.[45] Furthermore, He et al.